Zacks Research Brokers Reduce Earnings Estimates for PBH

Key Points

• Zacks Research lowered its Q4 2027 EPS estimate for Prestige Consumer Healthcare to $1.31 from $1.32, signaling slightly softer near-term expectations. The firm also trimmed other forward estimates, including Q1 2028 EPS at $1.19.
• Several analysts remain cautious on PBH: Jefferies cut its price target to $66 and Oppenheimer lowered its target to $65, though Oppenheimer kept an Outperform rating. Overall, the stock still carries a consensus rating of Moderate Buy with a $74.75 target price.
• Recent fundamentals were mixed, as the company last reported EPS of $1.14 versus $1.16 expected and revenue of $283.44 million versus $286.93 million estimated. Revenue also declined 2.4% year over year, while an insider sale by VP Jeffrey Zerillo added to the cautious tone.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Research analysts at Zacks Research reduced their Q4 2027 earnings per share (EPS) estimates for Prestige Consumer Healthcare in a report released on Thursday, May 7th. Zacks Research analyst Team now forecasts that the company will earn $1.31 per share for the quarter, down from their previous estimate of $1.32. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.54 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q1 2028 earnings at $1.19 EPS.

A number of other brokerages also recently weighed in on PBH. Jefferies Financial Group lowered their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a "hold" rating on the stock in a report on Friday, January 30th. Oppenheimer cut their price target on shares of Prestige Consumer Healthcare from $77.00 to $65.00 and set an "outperform" rating for the company in a research note on Thursday. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $74.75.

Prestige Consumer Healthcare Trading Down 0.0%

NYSE PBH opened at $52.53 on Monday. The company has a market cap of $2.49 billion, a PE ratio of 13.90, a PEG ratio of 1.57 and a beta of 0.40. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. Prestige Consumer Healthcare has a 12 month low of $51.24 and a 12 month high of $89.37. The stock has a 50 day moving average of $60.23 and a 200-day moving average of $61.92.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing analysts' consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The company had revenue of $283.44 million during the quarter, compared to the consensus estimate of $286.93 million. During the same quarter in the prior year, the business earned $1.22 earnings per share. The firm's revenue for the quarter was down 2.4% compared to the same quarter last year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Hedge funds have recently added to or reduced their stakes in the business. Lido Advisors LLC increased its holdings in shares of Prestige Consumer Healthcare by 5.4% in the fourth quarter. Lido Advisors LLC now owns 3,778 shares of the company's stock valued at $235,000 after purchasing an additional 192 shares during the last quarter. Profund Advisors LLC lifted its stake in shares of Prestige Consumer Healthcare by 3.2% during the 3rd quarter. Profund Advisors LLC now owns 6,770 shares of the company's stock worth $422,000 after buying an additional 207 shares during the last quarter. Cerity Partners LLC lifted its stake in shares of Prestige Consumer Healthcare by 5.9% during the 2nd quarter. Cerity Partners LLC now owns 3,884 shares of the company's stock worth $310,000 after buying an additional 218 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company's stock worth $26,000 after buying an additional 219 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of Prestige Consumer Healthcare by 69.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company's stock worth $35,000 after buying an additional 236 shares during the period. Institutional investors and hedge funds own 99.95% of the company's stock.

Insider Activity

In other news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the transaction, the vice president directly owned 42,820 shares in the company, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 2,553 shares of company stock valued at $151,444 over the last ninety days. Company insiders own 1.40% of the company's stock.

Prestige Consumer Healthcare News Roundup

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Oppenheimer kept an Outperform rating on PBH, even after trimming its price target to $65 from $77, suggesting the stock still has upside from recent levels. Article source
• Neutral Sentiment: Analysts continue to see a reasonable earnings trajectory for PBH, with consensus full-year EPS at $4.54 and Zacks projecting $4.76 for FY2027 and $5.05 for FY2028.
• Neutral Sentiment: A broader analyst note highlighted upcoming Q4 earnings expectations, but no new company guidance or major business update was reported in the article. Article source
• Negative Sentiment: Zacks Research cut EPS estimates for PBH, including lowering Q2 2028 estimates to $1.24 from $1.30 and trimming FY2027/FY2028 forecasts slightly, which can signal softer long-term expectations.
• Negative Sentiment: Insider selling added to the cautious tone: VP Jeffrey Zerillo sold shares in two May 5 transactions, including 1,207 shares and 346 shares, both disclosed under a pre-arranged trading plan.
• Negative Sentiment: PBH’s latest earnings report missed expectations, with EPS of $1.14 versus $1.16 expected and revenue of $283.44 million versus $286.93 million estimated, while revenue fell 2.4% year over year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.